Famotidine
Product Images NDC 50268-303

11 FDA label images from Avpak · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Famotidine (NDC 50268-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Table 1)

1 (Table 1)
Table titled 'Recommended Dosage and Duration of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function.' It lists various indications such as active duodenal ulcer, gastric ulcer, symptomatic nonerosive GERD, erosive esophagitis, pathological hypersecretory conditions, and reduction of risk of DU recurrence. Dosage recommendations range from 20 mg twice daily to 40 mg once daily or more frequent dosing. Recommended treatment durations vary from up to 6 weeks to up to 1 year or as clinically indicated. Footnotes provide additional clinical context and references.*
FDA Label Image

2 (Table 2)

2 (Table 2)
A table detailing the recommended maximum dosage of Famotidine tablets for adults and pediatric patients weighing 40 kg or more with moderate and severe renal impairment. The table organizes dosage recommendations by indication and creatinine clearance levels, including notes on alternate dosing regimens and clinical considerations relevant to renal impairment and specific conditions.*
FDA Label Image

Structural Formula (Fam00 0002 01)

Structural Formula (Fam00 0002 01)
Chemical structure diagram of Famotidine, showing the molecular arrangement of atoms and bonds in the active ingredient. The structure includes nitrogen, sulfur, and carbon atoms as indicated by the chemical formula components visible in the image.*
FDA Label Image

1 (Table 3)

1 (Table 3)
Data table showing serum concentrations of Famotidine associated with gastric acid reduction in pediatric and adult patients. It compares EC50 values (ng/mL) with means and standard deviations for pediatric patients, healthy adult subjects, and adult patients with upper GI bleeding, along with a footnote explaining the study context and methodology.*
FDA Label Image

1 (Table 4)

1 (Table 4)
A data table titled 'Table 4: Patients with Endoscopically Confirmed Healed Duodenal Ulcers' comparing healing rates at weeks 2 and 4 for Famotidine 40 mg at bedtime, Famotidine 20 mg twice daily, and placebo at bedtime groups.*
FDA Label Image

1 (Table 5)

1 (Table 5)
Table comparing the percentage of patients with endoscopically-confirmed healed gastric ulcers between famotidine 40 mg at bedtime and placebo in U.S. and International studies at weeks 4, 6, and 8. The table shows higher healing rates for famotidine groups compared to placebo in both studies with statistical significance indicated.*
FDA Label Image

1 (Table 6)

1 (Table 6)
A table titled "Patients with Improvement of Symptomatic GERD (N=376)" presenting percentages of improvement at week 6 for three groups: Famotidine 20 mg twice daily (82%), Famotidine 40 mg at bedtime (69%), and placebo at bedtime (62%). The sample sizes for each group are also shown.*
FDA Label Image

1 (Table 7)

1 (Table 7)
Table displaying the percentage of patients with endoscopic healing of erosive esophagitis in a U.S. study (N=318). It compares healing rates at week 6 and week 12 among three groups: Famotidine 40 mg twice daily (N=127), Famotidine 20 mg twice daily (N=125), and Placebo twice daily (N=66), showing higher percentages for the 40 mg dose group.*
FDA Label Image

1 (Table 8)

1 (Table 8)
A data table titled 'Patients with Endoscopic Healing of Erosive Esophagitis-International Study (N=440)'. The table compares percentages of patients healed at Week 6 and Week 12 under different treatments: Famotidine 40 mg twice daily (N=175), Famotidine 20 mg twice daily (N=93), and Ranitidine 150 mg twice daily (N=172). Percentages for Week 6 are 48%, 52%, and 42% respectively, and for Week 12 are 71%, 68%, and 60% respectively.*
FDA Label Image

Label 1 (Screen Shot 2014 10 07 At 9.39.30 Am)

Label 1 (Screen Shot 2014 10 07 At 9.39.30 Am)
The label for Famotidine Tablets USP shows a strength of 20 mg in a 50-tablet bottle (5 by 10 unit dose). The product is Rx only and manufactured for AvPAK, Inc. The label includes storage instructions, manufacturer location in Pulaski, TN, and barcode beneath the text.*
FDA Label Image

1 (304 15)

1 (304 15)
Packaging label for Famotidine Tablets USP 40 mg by AvPAK. The label indicates prescription-only status, packaging of 50 tablets in 5 strips of 10 each, and includes dosage information. It displays the NDC 50268-304-15, manufacturer details (AvKARE, Pulaski, TN), storage instructions, and a barcode. The label features the AvPAK logo and revision dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.